Absolute
Revitalizing immuno-oncology’s promise with next-generation T cell engagers
Precision
We are dedicated to helping people with cancer live longer, healthier lives.
Immuno-oncology has produced tremendous results for some cancer patients – even cures. But it still has vast untapped potential to help those whose cancers do not respond to current treatments.
At Clasp Therapeutics, we are expanding the reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. This approach enables a highly selective paradigm where every patient has the opportunity to respond to treatment.
Using cancer-specific markers to precisely and selectively target tumor cells for destruction
Clasp targets mutated protein fragments, or peptides, that are displayed by specialized HLA molecules on the surfaces of cancer cells. This approach opens up the possibility of targeting the vast majority of cancer-driving proteins that are expressed exclusively inside the cell, and thus invisible to traditional antibody-like drugs.
Oncogenic drivers enable exquisite tumor specificity
Achieving high-precision anti-tumor activity with antibody-like T cell engagers
We target these cancer-specific protein fragments with T cell engagers (TCEs), which are designed to draw T cells into close contact with tumor cells. The resulting immune synapse is highly similar to a natural HLA molecule-T cell receptor interface, triggering T cells to destroy tumor cells, while sparing non-malignant cells.
Modular patient- and tumor-specific TCEs
Creating precision treatment at-scale across a spectrum of driver mutations
Each of our TCEs is tailored to a specific combination of driver mutation and patient immune (HLA) type. This engineering enables a highly selective patient profile, while at the same time allowing us to develop a suite of TCEs with potential to treat large numbers of patients across many different driver mutations in many different cancer types. Our pipeline will continue to grow as more driver mutations are discovered.
Achieving precision by targeting cancer's drivers
At Clasp we are motivated by a deep commitment to translating cutting-edge research into meaningful medicines for patients. We merge a deep understanding of cancer genetics with extensive experience growing successful clinical-stage immuno-oncology companies to develop meaningful innovations for people suffering from cancer. We foster an environment of passion, inclusion and true teamwork.
Investors
Join the Clasp Team
We are an ambitious team that is committed to innovating and expanding the clinical potential of the latest discoveries in oncology. Join us in our drive to advance new therapies.
If you see yourself as a part of our team, send your resume and cover letter to careers@clasptx.com.
Press Releases
& Media
Collaborate with Clasp
Clasp welcomes discussions with potential partners around developing TCEs that are highly tumor-specific. To explore collaboration opportunities, email partner@clasptx.com.
EMAIL US DIRECTLY
PARTNER
partner@clasptx.com
MEDIA
media@clasptx.com
CAREERS
careers@clasptx.com
GENERAL INQUIRES
info@clasptx.com
OUR LOCATIONS
Rockville, MD
1450 Research Blvd., Suite 120
Cambridge, MA
One Kendall Square